Saturday 17 October 2026 Export KZIA’s income statement to Excel — free account

Novogen Limited

KZIA Healthcare Biotechnology

Novogen Limited’s revenue for fiscal 2025 (year ended June 2025) was $1.2 million, down 24.7% from fiscal 2024.

7.25 0.15 −2.03%

Follow KZIA

Alert me

Market cap: $84.6M
P/E: 0.0×
Fwd P/E: −19.4×
Dividend yield: —
F-score: 4/9
Altman Z: −39.89
Beneish M: −9.60
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 92.55%

Capital & Financial Ratios $m

Market Cap 84.58

Revenue —

Net Income (46.02)

Free Cash Flow (26.63)

Net Debt (45.53)

Current Ratio 2.87

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (19.40)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 6.41%

Next Y EPS Growth (38.02%)

Next Y revenue growth (62.07%)

Next 5Y EPS Growth (17.07%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/FCF against its own 10 years 100.00%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'25
Cash	4	1	3	46
Receivables	3	3	0	0
Inventory	—	—	—	—
Other	1	0	0	0
	7	4	3	46

	2023	2024	2025	Q'25
Payables	3	10	7	6
ST’ Debt	1	0	0	0
Other	1	7	2	10
	5	17	9	16

Compound Annual Growth %

	10y	5y	3y
Sales	33.40%	11.56%	297.51%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	1
’24	—	—	—	—	2
’23	—	—	—	—	0
’22	—	—	—	—	0
’21	—	—	—	—	11
’20	—	—	—	—	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(9)
’24	—	—	—	—	(6)
’23	—	—	—	—	(10)
’22	—	—	—	—	(17)
’21	—	—	—	—	(7)
’20	—	—	—	—	(6)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	(6)	—
’25	—	(9)	—	(5)	(9)
’24	—	(6)	—	(4)	(6)
’23	—	(10)	—	(6)	(10)
’22	—	(17)	—	(8)	(17)
’21	—	(7)	—	(9)	(7)
’20	—	(6)	—	(2)	(6)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(12.24)
’24	—	—	—	—	(33.30)
’23	—	—	—	—	(38.00)
’22	—	—	—	—	(67.50)
’21	—	—	—	—	(26.50)
’20	—	—	—	—	(65.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	278.00	81.50	102.00	106.50	123.50	344.50	25.00	16.00	8.75	2.86	Analyst estimates 2026–2028 Powerpack
	High	570.00	380.00	334.00	487.00	792.50	744.50	439.50	84.00	79.00	17.40
People
People	Employees	16	16	5	5	8	11	13	—	12	6
	Revenue/emp, $m	0.03	0.01	0.02	0.22	0.09	1.03	0.00	0.00	0.14	0.21
Income, $m
Income, $m	Revenue	1	0	0	1	1	11	0	0	2	1
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	(6,577.76)	100.00	100.00	100.00
	EBT	(17)	(8)	(5)	(8)	(9)	(7)	(18)	(14)	(18)	(15)
	EBT margin, %	(2,993.79)	(4,365.53)	(5,328.82)	(675.30)	(1,203.27)	(58.49)	(92,597.45)	(89,485.26)	(1,085.00)	(1,180.84)
	Net income	(17)	(8)	(5)	(7)	(8)	(6)	(18)	(14)	(18)	(13)
	Depreciation	1	1	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	6.51	2.01	0.95	9.73	4.88	48.35	0.07	0.04	3.10	1.12
	Earnings	(195.07)	(85.94)	(48.50)	(62.50)	(65.00)	(26.50)	(67.50)	(38.00)	(33.30)	(12.24)
	Cash flow	(192.23)	(92.10)	(69.37)	(41.76)	(40.49)	(28.93)	(62.34)	(27.68)	(11.91)	(7.85)
	Capex	(8.38)	(0.16)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(200.60)	(92.26)	(69.37)	(41.76)	(40.49)	(28.93)	(62.34)	(27.68)	(11.91)	(7.85)
	Book value	544.44	204.08	154.11	88.28	64.92	120.20	51.05	22.01	(12.46)	(4.91)
	Shares, m	0	0	0	0	0	0	0	0	1	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	EV/Sales	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	EV/FCF	1.58	0.29	0.17	0.19	0.38	0.87	0.13	0.06	0.03	0.10
Cash, $m
Cash, $m	Operating cash flow	(16)	(9)	(7)	(5)	(6)	(7)	(17)	(10)	(6)	(9)
	Capex	(1)	0	—	—	—	—	—	—	—	—
	Free cash flow	(17)	(9)	(7)	(5)	(6)	(7)	(17)	(10)	(6)	(9)
Balance, $m
Balance, $m	Working capital	45	11	4	4	4	16	2	2	(13)	(6)
	Total debt	1	0	—	—	—	—	1	1	0	0
	Net debt	(46)	(11)	(5)	(4)	(6)	(21)	(4)	(2)	(1)	(3)
	Shareholders’ equity	47	19	15	10	9	28	14	8	(7)	(5)
Returns, %
Returns, %	ROA	(39.27)	(21.22)	(19.14)	(39.72)	(54.66)	(21.37)	(52.01)	(62.24)	(106.23)	(148.30)
	ROIC	(1,515.06)	(58.03)	(11.29)	(62.05)	(141.33)	(38.58)	(119.30)	(175.20)	0.00	0.00
	ROE	(41.00)	(24.51)	(27.52)	(58.60)	(85.26)	(33.32)	(85.55)	(127.36)	(2,275.77)	224.48

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2025 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TNYA Tenaya Therapeutics, Inc.	$91.6M	— (loss-making)	—	—	n/m	+76.45% (above 0%: growing)	100.00%	(3,971.89%)	Compare
RLYB Rallybio Corporation	$89.1M	2.0×	— (loss-making)	0.00%	n/m	+648.02% (above 0%: growing)	100.00%	0.00%	Compare
OKUR OnKure Therapeutics, Inc.	$86.3M	— (loss-making)	—	—	n/m	+22.05% (above 0%: growing)	0.00%	0.00%	Compare
KZIA Novogen Limited	$84.6M	— (loss-making)	— (loss-making)	—	−32.67% (below 0%: shrinking)	−51.71% (below 0%: shrinking)	0.00%	0.00%
AARD Aardvark Therapeutics, Inc.	$84.5M	— (loss-making)	—	—	n/m	−77.14% (below 0%: shrinking)	—	0.00%	Compare
CRBP Corbus Pharmaceuticals Holdings, Inc.	$83.8M	— (loss-making)	— (loss-making)	−92.09% (below 0%: shrinking)	n/m	−78.52% (below 0%: shrinking)	0.00%	0.00%	Compare
EQ Equillium, Inc.	$83.7M	— (loss-making)	— (loss-making)	−52.32% (below 0%: shrinking)	n/m	−38.67% (below 0%: shrinking)	100.00%	0.00%	Compare
NMRA Neumora Therapeutics, Inc.	$80.2M	— (loss-making)	—	—	n/m	+24.45% (above 0%: growing)	0.00%	0.00%	Compare
CLLS Cellectis S.A.	$79.9M	— (loss-making)	—	−62.05% (below 0%: shrinking)	n/m	−36.95% (below 0%: shrinking)	100.00%	(340.69%)	Compare
Median of peers	$84.1M	—	—	−57.18%	—	−7.45%	100.00%	0.00%

All 614 Biotechnology stocks →

Novogen Limited (KZIA) key facts

Concern: Novogen Limited’s revenue for fiscal 2025 (year ended June 2025) was $1.2 million, down 24.7% from fiscal 2024.
Novogen Limited (KZIA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KZIA traded at $7.25, a market capitalization of $84.6 million.
Return on equity was 224.5% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −39.89 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.